StockData
InflaRx N.V. logo

InflaRx N.V. (IFRX) stock

IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 5/30
$1.11−0.04 (-3.48%)

Close on Nov 18, 2026Market cap $80.25MP/E –Yield –

InflaRx r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was €25.72M, down 27.3% from the year before. Over ten years it grew 22.2% a year on average. The highest annual figure on record is €44.58M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025€25.72M-27.3%
FY2024Dec 31, 2024€35.36M-13.8%
FY2023Dec 31, 2023€41.02M+9.3%
FY2022Dec 31, 2022€37.53M+5.1%
FY2021Dec 31, 2021€35.70M+39.0%
FY2020Dec 31, 2020€25.68M-42.4%
FY2019Dec 31, 2019€44.58M+78.1%
FY2018Dec 31, 2018€25.03M+73.6%
FY2017Dec 31, 2017€14.41M+173.1%
FY2016Dec 31, 2016€5.28M+51.8%
FY2015Dec 31, 2015€3.48M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025€7.20M-36.3%
Q2 FY2024Jun 30, 2024€10.02M-19.8%
Q2 FY2023Jun 30, 2023€10.92M+117.0%
Q2 FY2022Jun 30, 2022€11.18M–
Q2 FY2021Jun 30, 2021€11.30M–
Q2 FY2019Jun 30, 2019€12.50M–
Q2 FY2018Jun 30, 2018€5.03M–

More InflaRx figures

See a number that looks wrong?